- Home
- IFRX vs IKNA Comparison
IFRX vs IKNA Comparison
Compare IFRX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- IKNA
- Stock Information
- Founded
- IFRX 2007
- IKNA 2016
- Country
- IFRX Germany
- IKNA United States
- Employees
- IFRX N/A
- IKNA N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- IKNA Health Care
- Exchange
- IFRX Nasdaq
- IKNA Nasdaq
- Market Cap
- IFRX 56.4M
- IKNA 61.8M
- IPO Year
- IFRX 2017
- IKNA 2021
- Fundamental
- Price
- IFRX $0.79
- IKNA $1.32
- Analyst Decision
- IFRX Strong Buy
- IKNA Strong Buy
- Analyst Count
- IFRX 4
- IKNA 1
- Target Price
- IFRX $7.75
- IKNA $4.00
- AVG Volume (30 Days)
- IFRX 282.5K
- IKNA 59.9K
- Earning Date
- IFRX 08-07-2025
- IKNA 08-07-2025
- Dividend Yield
- IFRX N/A
- IKNA N/A
- EPS Growth
- IFRX N/A
- IKNA N/A
- EPS
- IFRX N/A
- IKNA N/A
- Revenue
- IFRX $140,242.00
- IKNA N/A
- Revenue This Year
- IFRX N/A
- IKNA N/A
- Revenue Next Year
- IFRX $6,309.47
- IKNA N/A
- P/E Ratio
- IFRX N/A
- IKNA N/A
- Revenue Growth
- IFRX 30.90
- IKNA N/A
- 52 Week Low
- IFRX $0.71
- IKNA $0.97
- 52 Week High
- IFRX $2.82
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- IFRX 37.43
- IKNA 51.66
- Support Level
- IFRX $0.78
- IKNA $1.31
- Resistance Level
- IFRX $0.83
- IKNA $1.36
- Average True Range (ATR)
- IFRX 0.04
- IKNA 0.04
- MACD
- IFRX 0.03
- IKNA -0.01
- Stochastic Oscillator
- IFRX 52.00
- IKNA 13.61
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.